SCHEMBL24570677

SCHEMBL24570677

OCc1ccc(Oc2ccc(F)cc2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
ALDH1A1 P00352 1/20 0.58
HSPB1 P04792 1/20 0.51
HTT P42858 1/20 0.44
MLNR O43193 1/20 0.43
CYP2D6 P10635 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
HRH3 Q9Y5N1 5/20 0.42
LTA4H P09960 1/20 0.42
PRKAA2 P54646 1/20 0.42
LIPE Q05469 1/20 0.41
MMP13 P45452 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380974 0.83 MEN1 (0.63) MEN1KMT2AKDM4EL3MBTL1ALDH1A1
SCHEMBL4597878 0.83 KDM4E (0.54) MEN1KMT2AKDM4EL3MBTL1ALDH1A1
SCHEMBL30744447 0.83 MEN1 (0.63) MEN1KMT2AKDM4EL3MBTL1ALDH1A1
SCHEMBL23361553 0.83 KDM4E (0.58) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL8019976 0.83 P2RX3 (0.48) L3MBTL1HTTEGLN1HRH3LTA4H
SCHEMBL29873318 0.83 KDM4E (0.58) MEN1KMT2AKDM4EALDH1A1HTT
SCHEMBL8007367 0.83 RAB9A (0.44) MEN1KMT2AKDM4EL3MBTL1ALDH1A1
SCHEMBL12967186 0.83 MEN1 (0.58) MEN1KMT2AKDM4EL3MBTL1ALDH1A1
SCHEMBL510046 0.83 LTA4H (0.58) ALDH1A1HTTLTA4HMMP13OPRM1
SCHEMBL15442301 0.83 LMNA (0.43) MEN1KMT2AKDM4EL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083908-A1 TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS ALIVEXIS, INC. (JP) 2024-03-14 US disclosed
EP-4269415-A1 TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND Modulus Discovery, Inc. (JP) 2023-11-01 EP disclosed
CN-116583286-A Tetrahydrothienopyrimidine sulfonamide compounds 某久拉斯株式会社 2023-08-11 CN disclosed
WO-2022138812-A1 TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND モジュラス株式会社 2022-06-30 WO disclosed
WO-2022138812-A1 TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND モジュラス株式会社 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083908-A1 TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS TYMS, TYMP, TPMT MEN1 267/4885KMT2A 321/4885KDM4E 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.